Mapping the Invisible Architecture of Disease: Spatial Multi-Omics Technologies, Computational Integration, and the Path Toward Clinical Translation
Integrative Biomedical Research · 01.04.2026 · 10 (1) · 1-8
DOI: 10.25163/biomedical.10110883 ↗Kurz gefasst
Fachartikel in der Zeitschrift Integrative Biomedical Research, online erschienen am 01.04.2026.
Abstract (Originalsprache)
Tissue is not a bag of cells. It is a coordinated, three-dimensional community whose spatial organization shapes development, homeostasis, and disease, yet this organization is destroyed the moment tissue is dissociated for conventional sequencing. Spatial multi-omics has emerged to close that gap, but the field remains fragmented across technologies, computational strategies, and clinical settings that rarely speak to one another. We conducted a structured narrative synthesis of the spatial multi-omics literature (2016-2026), organized around a five-branch conceptual framework spanning molecular hierarchy, next-generation sequencing- and imaging-based platforms, computational fusion architectures, clinical translation, and deployment barriers. Sources were drawn from peer-reviewed journals indexed in PubMed, Scopus, and Web of Science, supplemented by platform-defining primary reports. Ninety-plus sources converged on several consistent patterns. NGS-based platforms (Visium, Visium HD, Stereo-seq, DBiT-seq) trade spatial precision for unbiased transcriptomic breadth, whereas imaging-based platforms (MERFISH, seqFISH+, Xenium, CosMx) achieve subcellular fidelity at the cost of panel size. Intermediate-fusion architectures, particularly graph-neural-network models such as SpatialGlue, SWITCH, and MultiGATE, now outperform early- and late-fusion approaches for preserving native spatial topology. Clinically, spatially resolved immune-proximity and stromal-exclusion scores outperform bulk immunohistochemistry in predicting immunotherapy response, and multi-omic mapping has nominated actionable targets in oncology, cardiology, and nephrology. Persistent barriers include FFPE incompatibility, terabyte-scale computational burden, algorithmic opacity, and a severe European-ancestry bias that erodes polygenic score accuracy by up to 78% in African-ancestry cohorts. Spatial multi-omics is approaching, but has not yet reached, routine clinical deployment; standardized pre-analytical protocols, interpretable AI, and globally representative biobanking are the rate-limiting steps for translation.
Zitieren
APA
(2026). Mapping the Invisible Architecture of Disease: Spatial Multi-Omics Technologies, Computational Integration, and the Path Toward Clinical Translation. Integrative Biomedical Research, 10(1), 1-8. https://doi.org/10.25163/biomedical.10110883
Vancouver
Mapping the Invisible Architecture of Disease: Spatial Multi-Omics Technologies, Computational Integration, and the Path Toward Clinical Translation. Integrative Biomedical Research. 2026;10(1):1-8. doi:10.25163/biomedical.10110883
BibTeX
@article{euvimed2026,
title = {Mapping the Invisible Architecture of Disease: Spatial Multi-Omics Technologies, Computational Integration, and the Path Toward Clinical Translation},
journal = {Integrative Biomedical Research},
year = {2026},
volume = {10},
number = {1},
pages = {1--8},
doi = {10.25163/biomedical.10110883}
}
EUVIMED